Literature DB >> 18752047

Reduced mobilisation of hematopoietic stem cells after hepatic resection for malignant liver disease.

Marinella Menegazzo1, Paola Bagatella, Piero Marson, Carla Donadel, Giustina De Silvestro, Augusto Corsini.   

Abstract

Recent studies have demonstrated that hematopoietic stem cells (HSCs) can mobilize following liver resection, thus contributing to the repair of hepatic damage. Aim of this study has been to determine whether the nature of the hepatic lesion (benign vs. malignant disease) can give rise to a different degree of mobilisation of HSCs. Two groups of patients were selected: the first included seven patients undergoing hepatic resection (five major and two minor) for a benign liver disease (focal nodular hyperplasia, hemangioma cavernosa, angioma, biliary adenofibroma) and the second included seven patients undergoing hepatic resection (five major and two minor) for a malignant (either primary or secondary) liver disease. White blood cell count and CD34+ (percentage and total number) at time T(0) (basal value before surgery) and at time T(1) (value on the sixth-eighth day after surgery) have been evaluated by standard methods. In the group undergoing hepatic resection for a benign liver disease, a significant increase of CD34+ cells, both in percentage (0.082 +/- 0.043 vs. 0.048 +/- 0,026, p = 0.041) and in absolute number (8.14 +/- 5.95 vs. 3.26 +/- 2.63, p = 0.018) have been documented, as opposed to the group of patients affected with a malignant liver disease, where no significant variation has been observed (CD34+ %: 0.044 +/- 0.033 vs. 0.041 +/- 0.031, p: n.s.; CD34+ total number: 3.52 +/- 2.56 vs. 2.27 +/- 2.01, p = n.s.) These results show a different bone marrow response to the surgical liver resection depending on the nature of the lesion, thus emphasizing a reduced mobilisation of HSCs in the malignant diseases. Since it has been documented that the type of the hepatic lesion can induce a different regenerative response, it has to be explained how the neoplastic lesions can negatively influence the mobilization of HSCs. It can be hypothesized that a variety of humoral factors, including stromal cell-derived factor, matrix metalloproteinases, hepatocyte growth factor and interleukin-8 can influence the process of mobilization of HSCs after liver resection surgery. These substances are also involved in the mechanisms of development and metastasising of many tumours. It is probably in this context that a reason may be found for the different mobilisation of hematopoietic stem cells, depending on the nature of the hepatic lesion treated, that was encountered in this study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752047     DOI: 10.1007/s12253-008-9091-3

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  28 in total

Review 1.  Hematopoietic stem cells and aging.

Authors:  A Globerson
Journal:  Exp Gerontol       Date:  1999-04       Impact factor: 4.032

Review 2.  Biology of IL-8-induced stem cell mobilization.

Authors:  W E Fibbe; J F Pruijt; G A Velders; G Opdenakker; Y van Kooyk; C G Figdor; R Willemze
Journal:  Ann N Y Acad Sci       Date:  1999-04-30       Impact factor: 5.691

Review 3.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.

Authors:  Robert Visse; Hideaki Nagase
Journal:  Circ Res       Date:  2003-05-02       Impact factor: 17.367

4.  Treatment of stroke in rat with intracarotid administration of marrow stromal cells.

Authors:  Y Li; J Chen; L Wang; M Lu; M Chopp
Journal:  Neurology       Date:  2001-06-26       Impact factor: 9.910

5.  Mobilization of peripheral blood hematopoietic stem cells following liver resection surgery.

Authors:  Giustina De Silvestro; Maria Vicarioto; Carla Donadel; Marinella Menegazzo; Piero Marson; Augusto Corsini
Journal:  Hepatogastroenterology       Date:  2004 May-Jun

6.  Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis.

Authors:  Sylvia Fong; Yoko Itahana; Tomoki Sumida; Jarnail Singh; Jean-Philippe Coppe; Yong Liu; Peter C Richards; James L Bennington; Nancy M Lee; Robert J Debs; Pierre-Yves Desprez
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-24       Impact factor: 11.205

7.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1.

Authors:  Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

8.  Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand.

Authors:  Beate Heissig; Koichi Hattori; Sergio Dias; Matthias Friedrich; Barbara Ferris; Neil R Hackett; Ronald G Crystal; Peter Besmer; David Lyden; Malcolm A S Moore; Zena Werb; Shahin Rafii
Journal:  Cell       Date:  2002-05-31       Impact factor: 41.582

Review 9.  Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt.

Authors:  C S Potten; M Loeffler
Journal:  Development       Date:  1990-12       Impact factor: 6.868

10.  Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo.

Authors:  C R Bjornson; R L Rietze; B A Reynolds; M C Magli; A L Vescovi
Journal:  Science       Date:  1999-01-22       Impact factor: 47.728

View more
  2 in total

1.  Differential bone marrow hematopoietic stem cells mobilization in hepatectomized patients.

Authors:  Carmen Herencia; Antonio Rodríguez-Ariza; Antonio Canalejo; Alvaro Naranjo; F Javier Briceño; Pedro López-Cillero; Manuel De la Mata; Juan R Muñoz-Castañeda
Journal:  J Gastrointest Surg       Date:  2011-04-22       Impact factor: 3.452

2.  Atypical Biliary Adenofibroma of the Liver: Related Treatment and Performance.

Authors:  Shao-Ru Liu; Qi Zhu; Ming-Bin Feng; Qing Yan; Tai-Feng Zhu; Lei-Bo Xu
Journal:  Case Rep Gastroenterol       Date:  2022-08-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.